FDA approves Mirikizumab-mrkz for Crohn’s disease
This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.
Medication topics
Mercaptopurine articles covering 6-MP immunomodulator treatment, safety monitoring, combination therapy, and IBD decisions. Access context emphasizes approvals, coverage, affordability, availability, and policy decisions.
1 article
This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.